A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia Heterogeneity of myelodysplastic syndromes (MDS) and related neoplasms 1 is a reflection of inherent diversity of molecular lesions and their combinations that likely determine morphological and clinical features and/or the pace of evolution into secondary acute myeloid leukemia (sAML). Next-generation sequencing and single-nucleotide polymorphism arrays (SNP-A) have yielded increasingly defined spectra of somatic mutations and a growing understanding of their roles in pathogenesis and genotype-phenotype relationships. As such discoveries inch toward completion, [2] [3] [4] identification of the remaining relationships between driver mutations and clinical phenotypes may require resolution gains obtained by using multiple sources of information.
AT-rich interactive domain 2 (ARID2), which is located on chromosome 12q12, encodes a component of the SWI/SNF (SWItch/Sucrose Non-Fermentable)-B complex that is involved in chromatin remodeling. Among various SWI/SNF genes, multiple groups recently detected ARID2 mutations or deletions in various solid tumors. [5] [6] [7] [8] [9] These reports suggest that ARID2 is a global tumor suppressor gene in various cancers. With regard to hematological neoplasms, SMARCA4 (BRG1), which is a core component of both SWI/SNF-A and B, is essential for maintenance of stemness of AML. 10, 11 In addition, mutations of ARID1A and ARID1B, components of SWI/SNF-A, were identified in cases with acute promyelocytic leukemia (APL), in which ARID1B deficiency causes a block in differentiation. 12 These previous discoveries prompted us to investigate genetic defects in SWI/SNF components in MDS and its related neoplasms. Here, we report whole-exome sequencing-guided identification of novel ARID2 mutations in myeloid neoplasms. In this study, we aimed to elucidate the distinct impact of ARID2 defects on myeloid neoplasms. Even though somatic mutations of this gene were relatively rare, integrated analysis of multiple genetic methodologies allowed us to find other mechanisms of ARID2 deficiency and to shed light on a novel morphological phenotype of MDS associated with loss of ARID2 function. Somatic mutations, deletions and low expression may converge as alternate mechanisms of ARID2 inactivation.
We examined ARID2 (NM_152641; 1,835 amino acids) mutational status of a cohort of patients (n = 393) with various myeloid malignancies, including low-risk (n = 58) and high-risk (n = 35) MDS, MDS/myeloproliferative neoplasm (MPN) (n = 37), MPN (n = 21), sAML (n = 33) and de novo AML (n = 209) (Supplementary Table S1 ) by whole-exome sequencing and resequencing (Supplementary Table S2 ). ARID2 mutations were identified in 6 cases with MDS (n = 2), MDS/MPN (n = 1), MPN (n = 1) and de novo AML (n = 2), (Supplementary Table S3 ). All mutations were confirmed to be somatic using germline DNA (Figure 1a ). Among the 6 mutations, 5 (83%) were nonsense or frameshift, suggesting that loss of ARID2 function is pertinent to myeloid neoplasms. Amplicon deep sequencing and SNP-A karyotyping revealed that all of the mutations were heterozygous (Figures 1a and b) may also reflect ARID2 mutations arising in a hematopoietic stem cell capable of some differentiation into CD3+ T cells. In the tumor fraction, variant allele frequencies of ARID2 mutations were all high (27-48%, median = 43%), suggesting ARID2 mutations might be relatively early events (Figure 1b ). In 11 cell lines of myeloid leukemia, ARID2 mutations were not identified (Supplementary Table S4 ). Frequent identification of loss-of-function mutations in ARID2 prompted us to investigate copy number variations of this gene locus. For this purpose, a separate cohort of patients (n = 1080) with myeloid malignancies, including MDS (n = 362), MDS/MPN (n = 164), MPN (n = 35), sAML (n = 188) and de novo AML (n = 331) was subjected to SNP-A karyotyping (Supplementary Table S1 ). Copy number losses (deletions) of ARID2 locus (chr12q12) were identified in 8 cases with MDS (n = 5), sAML (n = 1) and de novo AML (n = 2), whereas focal gain lesions were not detected ( Figure 1a and Supplementary ARID2 1 1 1 1 1 1 1 1 1 1 1 1 1 (Figure 1c) . Taken together, in our cohort, ARID2 defects were present in ∼ 1% of cases (14 out of 1473).
According to our findings, we then comprehensively investigated ARID2-mediated myeloid neoplasms by clarifying additional genetic events in cases with ARID2 defects. Most common additional genetic events were mutations and deletions in genes harboring histone repressive mark, including EZH2 and JARID2, that were identified in 43% (6/14) of cases (Figure 2a and Supplementary Figure S1a) , suggesting synergetic effects of histone modification together with defective chromatin remodeling. Receptor tyrosine kinase pathway and RAS pathway genes were affected by mutations as secondary events in cases with ARID2-mediated myeloid neoplasms (Figure 2b ). Mutations and deletions of TP53 (n = 5), DNMT3A (n = 2) and TET2 (n = 1) were also identified. Whereas 3 (21%) cases were cytogenetically normal, complex karyotypes and trisomy 8 were found in 7 and 2 cases, respectively (Figure 2a) .
In five cases with ARID2 defects, serial sample sequencing or SNP-A analysis was performed to investigate clonal architecture. According to mutated clone size and cell fraction, ARID2 mutations and deletions tended to be acquired as early events followed by other mutations and copy number abnormalities (Figure 2b and Supplementary Figure S1b) . These findings suggest that defective ARID2 is likely to be an initial clonal event.
We next investigated genotype-phenotype associations of defective ARID2. Relative expression of wild-type ARID2 was significantly lower in MDS than in healthy donors (P = 0.02; Figure 2c ). A mean value of ARID2 relative expression showed 25% reduction in patients with MDS (95% confidence interval (CI) 0.67-0.80) compared with that in healthy donors (95% CI 0.82-1.12).
To further assess the features of ARID2 deficiency, an independent pathologist examined bone marrow cell morphologies of the cases with ARID2 mutation and deletion (n = 8). In addition to the megaloblastoid erythorid and hypogranular myeloid cells, progressive maturation was identified in myeloid and erythroid lineages. Most prominent findings were megakaryocytic dysplasias, which were seen in all of 8 cases with ARID2 defects, including hypolobated forms in 7 cases (Supplementary  Table S5 and Figure 2d ). We also collected information of bone marrow dysplasia from 311 MDS cases without ARID2 defects. Among these, 41.9% (n = 127) and 65.0% (n = 197) of cases showed myeloid and erythroid dysplasias, respectively (Supplementary Table S5 ). Among cases with ARID2 defects (n = 8), 50% (n = 4) and 50% (n = 4) showed myeloid and erythroid dysplasias, respectively. The frequencies of these dysplasias were not significantly different between the cases with and without ARID2 defects. In contrast, megakaryocytic dysplasia was significantly more frequently observed in cases with ARID2 defects (100%; n = 8/8) than in those without ARID2 defects (51.5%; n = 156/311) (P = 0.0078). These findings suggest that megakaryocytic dysplasia is associated with ARID2 defects.
Our comprehensive study by whole-exome sequencing, RNA sequencing and SNP-A, elucidated a role for a novel tumor suppressor gene, ARID2, in myeloid neoplasms. Loss of ARID2 function due to its genomic defects is frequently acquired in early stage of myelodysplasia. Intriguingly, ARID2 deficiency represents hypolobated forms of megakaryocytes. Overall, these common features are shared by genetic and epigenetic defects leading to ARID2 deficiency.
ARID2 encodes a subunit of SWI/SNF-B (PBAF) complex that is involved in chromatin remodeling and transcription regulation. Together with the other SWI/SNF complex, SWI/SNF-A (BAF), the SWI/SNF system is essential for transcriptional activation and repression in mammalian cells. 13 Although homeostasis of this cellular machinery is strictly regulated for normal physiology, various deregulations of SWI/SNF because of genetic events can cause cancers in many tissues.
14 According to previous studies of AML, SMARCA4 is required for self-renewal capacity. 10, 11 Most recently, loss of function of ARID1A or ARID1B was reported in APL, in which ARID1B deficiency causes a block in differentiation. 12 Despite the lack of ARID2 mutations in APL, 12 we now identified multiple mutations of this gene in MDS and MDS/MPN cases. In contrast, ARID1A and ARID1B mutations were not identified in MDS or MDS/MPN. These findings suggest that mutations of the different components in SWI/SNF-A and -B complexes result in the presentation of distinct phenotypes with different functional consequences probably depending on downstream transcriptional targets.
To regulate differentiation genes, SWI/SNF complexes work with various histone modification enzymes, including methyltransferases and acetyltransferases. 15 Among these, polycomb repressive complex 2 (PRC2) is involved in trimethylation of histone H3 lysine 27 (H3K27), chromatin condensation and transcriptional repression. Genes for components of PRC2 were frequently affected by loss-of-function mutations and deletions in ARID2-deficient MDS cases. In contrast, PRC2 is frequently activated in solid tumors.
14 Accordingly, correlation between ARID2 deficiency and PRC2 dysfunction in myelodysplasia is likely tissue specific. Further studies of expression profiles associated with unique patterns of histone modification and DNA remodeling will be needed to clarify which target genes are responsible for their synergistic effects in MDS genesis.
Our main conclusion is that ARID2 defects attenuated by multiple mechanisms are early events in a subset of MDS cases characterized by distinct morphological features. Histone deacetylases (HDACs) are attractive therapeutic targets, and selective HDAC inhibitors (HDACi), alone or in combination with other anti-cancer agents, are promising treatment strategies in multiple myeloma (MM). [1] [2] [3] [4] To date, however, the effect of HDACi on immune regulation in the MM bone marrow (BM) microenvironment, as well as the therapeutic potential of combining selective HDACi with immune-based therapies, is undefined. Recent studies showed that besides histone modification, HDACs also modulate non-histone targets including immune regulatory molecules. 5, 6 For example, blockade of HDACs upregulates immunecheckpoints such as PD-1 ligand (PD-L1). 6 Moreover, the combination of HDACi with PD-1/PD-L1 checkpoint blockade significantly improves immunotherapy in a murine B16F10 model. 6 In MM, PD-L1 expression directly correlates with progression of disease, with highest levels in patients with relapsed/ refractory MM. 7, 8 Here, we utilized an orally bioavalable HDAC6 selective inhibitor ACY-241, currently in clinical trials, 9 to examine whether the combination of ACY-241 with anti-PD-L1 antibody enhances anti-MM immunity in the MM BM microenvironment. ) and MM cells, implicating pDCs in both MM pathogenesis and immune suppression. We showed that increased numbers of pDCs are present in MM patient BM versus normal BM. Importantly, pDCs in MM BM are relatively resistant to current therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; and confer immune dysfunction. 7, 10 Using our coculture model, we further delineated the immunosuppressive mechanism(s) that have a role during pDC-T-NK cell interactions with tumor cells. Specifically, we found that: (1) MM cells and pDCs expressed high surface levels of PD-L1, whereas T cells showed high PD-1 levels; and (2) PD-L1 on MM pDCs suppresses PD-1 expressing T-cell and NK cell immune function; and (3) blockade of PD-L1-PD-1 signaling axis by anti-PD-L1 Ab generates MM-specific CD8+ ctotoxic T lymphocyte (CTL) activity, as well as enhances NK cell-mediated MM cell cytolytic activity. Importantly, our co-culture Accepted article preview online 6 November 2017; advance online publication, 5 January 2018
